stocksBAFNAPH
BAFNAPH

Bafna Pharmaceuticals Ltd.

443.50+8.6 (+1.99%)
14 Oct, 12:00 AM

Annual Reports and Financial Documents

Bafna Pharmaceuticals Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.
20420132014201520162017201820192020202120222023202420252026
Annual Reports—FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Quarterly Results—————
Conference Calls———————————————
Presentations———————————————

Corporate Announcements and Regulatory Filings

Bafna Pharmaceuticals Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.
  1. Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 201812 Oct 2026
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
    Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026
  2. Closure of Trading Window26 Sept 2026
    Closure of Trading Window
    Intimation for Closure of Trading Window
  3. AGM11 Sept 2026
    Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
    We herewith enclose the Voting Results of the 31st Annual General Meeting of the Company held on September 11, 2026 along with the Scrutinizer Report.
  4. AGM11 Sept 2026
    Shareholder Meeting / Postal Ballot-Outcome of AGM
    We herewith enclose the Outcome / Proceedings of the 31st Annual General Meeting of the Company held on September 11, 2026.
  5. Newspaper Publication21 Aug 2026
    Announcement under Regulation 30 (LODR)-Newspaper Publication
    We herewith enclose the Newspaper Publication for the 31st Annual General Meeting of the Company published in ''Business Standard'' and ''Makkal Kural'' on August 20, 2026.
  6. AGM19 Aug 2026
    Notice Of 31St Annual General Meeting Of The Company For The F.Y 2025-2026
    We herewith enclose the Notice of 31st Annual General Meeting of the Company scheduled to be held on Friday, September 11, 2026 at 10.00 A.M along with the Annual Report of the Company ....
  7. Reg. 34 (1) Annual Report19 Aug 2026
    Reg. 34 (1) Annual Report.
    We herewith enclose the Annual Report of the Company for the F.Y 2025-2026.
  8. Newspaper Publication14 Aug 2026
    Announcement under Regulation 30 (LODR)-Newspaper Publication
    Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter ended June 30, 2026 as published in ''Business Standard'' and ''Makkal Kural'' on August 13, 2026.
  9. Book Closure13 Aug 2026
    Book Closure For 31St Annual General Meeting
    We herewith enclose the intimation for Book Closure and Cut-Off dates for the purpose of 31st Annual General Meeting of the Company.
  10. AGM13 Aug 2026
    Shareholder Meeting - 31St AGM On September 11, 2026
    We hereby inform that the 31st Annual General Meeting (AGM) of the Company is scheduled to be held on Friday, September 11, 2026 at 10.00 A.M through Video Conferencing (VC) / Other Audio ....
  11. Outcome of Board Meeting11 Aug 2026
    Board Meeting Outcome for The Board Meeting Held On 11/08/2026
    We hereby inform you that the Board of Directors in their meeting held on August 11, 2026 inter-alia considered and approved i) Unaudited Financial Results of the Company for the Quarter ....
  12. Board Meeting5 Aug 2026
    Board Meeting Intimation for Meeting Scheduled On August 11, 2026
    Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve the Un-Audited Financial ....
  13. Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 20189 Jul 2026
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
    Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2026.
  14. Closure of Trading Window26 Jun 2026
    Closure of Trading Window
    Intimation for Closure of Trading Window
  15. Change in Directorate22 Jun 2026
    Announcement under Regulation 30 (LODR)-Change in Directorate
    Intimation for retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company upon completion of his first term, with effect from close of business hours on June 22, 2026.
  16. Retirement22 Jun 2026
    Announcement under Regulation 30 (LODR)-Retirement
    Intimation for retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company upon completion of his first term, with effect from close of business hours on June 22, 2026.
  17. Newspaper Publication1 Jun 2026
    Announcement under Regulation 30 (LODR)-Newspaper Publication
    Newspaper Publication for the Audited Financial Results of the Company for the Quarter & Year ended March 31, 2026 as published in "Financial Express" and "Makkal Kural" on May 31, 2026.
  18. Outcome of Board Meeting29 May 2026
    Board Meeting Outcome for Outcome Of The Board Meeting Held On May 29, 2026
    We hereby inform you that the Board of Directors in their meeting held on May 29, 2026 inter-alia considered and approved the Audited Financial Results of the Company along with the Auditor's ....
  19. Board Meeting21 May 2026
    Board Meeting Intimation for Meeting Scheduled On May 29, 2026
    Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the Audited Financial ....
  20. General15 Apr 2026
    Clarification On Price Movement
    We hereby submit our response to the Clarification sought by the Stock Exchange regarding the movement in the Share Price of the Company.

Frequently Asked Questions

Where can I download the annual report of Bafna Pharmaceuticals Ltd.?
Annual reports of Bafna Pharmaceuticals Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.
Where can I find the quarterly results of Bafna Pharmaceuticals Ltd.?
Quarterly earnings results and presentations of Bafna Pharmaceuticals Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.
Does Bafna Pharmaceuticals Ltd. publish earnings call transcripts?
Earnings call transcripts of Bafna Pharmaceuticals Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.
Where can I find investor presentations of Bafna Pharmaceuticals Ltd.?
Investor presentations and annual day presentations of Bafna Pharmaceuticals Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.
What are the recent corporate announcements of Bafna Pharmaceuticals Ltd.?
Corporate announcements and regulatory filings of Bafna Pharmaceuticals Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.
How do I access the regulatory filings of Bafna Pharmaceuticals Ltd.?
Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Bafna Pharmaceuticals Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.
What is the ISIN of Bafna Pharmaceuticals Ltd.?
The ISIN (International Securities Identification Number) of Bafna Pharmaceuticals Ltd. is INE878I01022. This is the unique identifier used across exchanges and depositories.
On which stock exchange is Bafna Pharmaceuticals Ltd. listed?
Bafna Pharmaceuticals Ltd. is listed on NSE and BSE. The NSE symbol is BAFNAPH and the BSE code is -.
Where can I find the shareholding pattern of Bafna Pharmaceuticals Ltd.?
The quarterly shareholding pattern of Bafna Pharmaceuticals Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.
How current is the data for Bafna Pharmaceuticals Ltd. on Sharpely?
Share price data for Bafna Pharmaceuticals Ltd. is updated as of 14 Oct 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.